Minerva Neurosciences Inc NERV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NERV is a good fit for your portfolio.
News
-
Minerva Neurosciences Shares Slide on Latest FDA Roluperidone Setback
-
FDA Turns Away Minerva's Roluperidone Schizophrenia Drug
-
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
-
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
-
Minerva Neurosciences Gets FDA Confirmation for NDA for Roluperidone
-
Minerva Neurosciences Shares Rise 25% FDA Files NDA for Roluperidone
Trading Information
- Previous Close Price
- $2.50
- Day Range
- $2.45–2.53
- 52-Week Range
- $2.26–13.49
- Bid/Ask
- $2.48 / $2.73
- Market Cap
- $17.34 Mil
- Volume/Avg
- 11,385 / 131,847
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 9
Comparables
Valuation
|
Metric
|
NERV
|
ITCI
|
RYTM
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 11.73 | 13.34 |
Price/Sales | — | 14.94 | 28.39 |
Price/Cash Flow | — | — | — |
Price/Earnings
NERV
ITCI
RYTM
Financial Strength
|
Metric
|
NERV
|
ITCI
|
RYTM
|
|---|---|---|---|
Quick Ratio | 12.25 | 4.95 | 5.27 |
Current Ratio | 12.57 | 5.41 | 5.58 |
Interest Coverage | −2.62 | — | −13.26 |
Quick Ratio
NERV
ITCI
RYTM
Profitability
|
Metric
|
NERV
|
ITCI
|
RYTM
|
|---|---|---|---|
Return on Assets (Normalized) | −47.71% | −13.47% | −46.12% |
Return on Equity (Normalized) | — | −15.88% | −76.97% |
Return on Invested Capital (Normalized) | — | −17.96% | −76.40% |
Return on Assets
NERV
ITCI
RYTM
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cmmzvhdjl | Czz | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fzpgzbt | Ntxqfwn | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jrfctsml | Xqcvr | $98.1 Bil | |
MRNA
| Moderna Inc | Pwxxkbb | Jbdj | $39.1 Bil | |
ARGX
| argenx SE ADR | Lmfdnfs | Xkvm | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Cyhmthrz | Bwyt | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jyzkfpz | Qcnjyd | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Twwtkrjl | Tcxbfl | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Pgmrtbkfg | Swzttv | $12.5 Bil | |
INCY
| Incyte Corp | Gfnqkpxpt | Fcmftt | $11.9 Bil |